The FDA's advisory committee voted 10 to 3 that the efficacy results from Replimune's IGNYTE study on RP1 combined with nivolumab for advanced melanoma are evaluable and clinically meaningful. This positive outcome supports the ongoing FDA review of the Biologics License Application for RP1, a novel oncolytic immunotherapy targeting patients who progressed after anti-PD-1 therapy. The FDA's target decision date is August 2, 2026, marking a significant step toward potential approval of this new treatment option for advanced melanoma patients.
Telix Pharmaceuticals announced it will release its financial results for the half-year ended June 30, 2026, on August 20, 2026. An investor webcast and conference call will be held the same day to discuss the results. Telix is a global radiopharmace...
Inno Holdings Inc., a Texas-based electronic products trading company, announced that its common stock will resume trading on The Nasdaq Capital Market on July 31, 2026, around noon Eastern Time. This follows a trading halt imposed by Nasdaq under Co...
SAP Fioneer has introduced its Cloud Accounting Subledger, a cloud-based solution designed to help financial institutions manage complex multi-GAAP accounting requirements. The platform consolidates accounting standards like IFRS and US GAAP into a s...
DBV Technologies announced a $50 million capital raise through the issuance of new American Depositary Shares (ADS) under its At-The-Market (ATM) program on Nasdaq. The placement involves issuing 3.66 million ADS, each representing five ordinary shar...
Cinemark's price target was increased to $40 from $35 following a record second-quarter revenue of $1.09 billion and earnings per share of $1.19, both surpassing analyst expectations. This reflects a strong recovery in the movie theater industry, dri...
